Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more ...

Gilead increased CEO Daniel O’Day's compensation by 20% in 2025 to $28.4 million, putting him among the highest-paid chief ...

A common drug combo for Parkinson’s disease will require a new FDA warning after the agency flagged 14 cases of seizures in ...

Amid an outpouring of pharma investment dollars into China, Novartis is the latest multinational drugmaker lining up to ...

Since its introduction nine months ago, the FDA’s national priority voucher pilot program has attracted intrigue and fierce ...

Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure ...

On top of the newly approved lung disorder pill Brinsupri, which Insmed expects will achieve blockbuster sales this year, the New Jersey company has ...

As pharmaceutical companies face increasing pressure to produce more content across more channels, the Medical, Legal, and ...

It’s time once again for Fierce Pharma Marketing’s annual #FierceMadness tournament. This time around, we're watching 64 ...

The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...